医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Terns Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

2020年05月26日 PM06:00
このエントリーをはてなブックマークに追加


 

FOSTER CITY, Calif. & SHANGHAI

Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today announced that Erin Quirk, M.D., Chief Medical Officer, will present a corporate overview and update on the Company’s lead clinical programs at the Jefferies Virtual Healthcare Conference taking place June 2-4, 2020. Terns will present at 4:30 pm ET (1:30 p.m. PT) on June 2.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients.

For more information, visit www.ternspharma.com and www.ternspharma.com.cn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005255/en/

CONTACT

US Media Contact:

Margaret Robinson

(415) 690-0084

China Media Contact:

Zhou Zhou

+86 13482103703

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物